MedTrace Logo

A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

NCT07583030 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-05-13

No results posted yet for this study

Summary

This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.

Conditions

  • Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)
  • Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)
  • Progressive Multiple Sclerosis (PMS)
  • Relapsed/Refractory Myasthenia Gravis(r/r MS)

Interventions

BIOLOGICAL

LVIVO-TaVec400 product

Each subject will be given a single-dose LVIVO-TaVec400 via intravenous infusion.

Sponsors & Collaborators

  • Nanjing Legend Biotech Co.

    collaborator INDUSTRY

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Qiubai Li · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-20
Primary Completion
2028-09-20
Completion
2041-09-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07583030 on ClinicalTrials.gov